Xponance Inc. Has $8.53 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Xponance Inc. reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 33.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,293 shares of the medical research company’s stock after selling 46,106 shares during the quarter. Xponance Inc.’s holdings in Edwards Lifesciences were worth $8,525,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of EW. 9258 Wealth Management LLC boosted its stake in Edwards Lifesciences by 24.8% during the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock worth $803,000 after buying an additional 2,093 shares in the last quarter. Gryphon Financial Partners LLC lifted its holdings in Edwards Lifesciences by 35.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock worth $492,000 after buying an additional 1,698 shares in the last quarter. Commerce Bank boosted its position in Edwards Lifesciences by 0.6% in the 4th quarter. Commerce Bank now owns 37,938 shares of the medical research company’s stock valued at $2,893,000 after buying an additional 216 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $3,182,000. Finally, Congress Wealth Management LLC DE lifted its stake in shares of Edwards Lifesciences by 16.3% during the fourth quarter. Congress Wealth Management LLC DE now owns 7,650 shares of the medical research company’s stock valued at $583,000 after acquiring an additional 1,070 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.7 %

Shares of EW opened at $67.33 on Tuesday. The firm has a market cap of $40.57 billion, a price-to-earnings ratio of 29.02, a PEG ratio of 2.85 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The business’s fifty day moving average is $69.45 and its 200-day moving average is $82.61. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the previous year, the firm posted $0.66 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EW. Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. UBS Group decreased their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Finally, Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Sixteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $79.82.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,250 shares of company stock worth $1,218,138. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.